Summary
The measurement of plasma drug concentrations provides no insight into the relationship between the free and the plasma-protein-bound fractions of drugs. Plasma protein binding may decrease in renal disease due to uremia, hypoalbuminemia, or due to drug interactions. Decreased plasma protein binding leads to an increase in free plasma fraction causing an increase in volume of distribution and a shorter elimination half life. The increase in the apparent volume of distribution and the shorter elimination half life cause a decrease in total plasma concentration. Therefore, the free drug concentration is more reliable than the total plasma concentration for therapeutic drug monitoring. However, the free amount in plasma and in tissue and the tissue-bound amount remain unchanged under steady state conditions. Thus, a decrease in plasma protein binding in renal disease usually does not lead to increased drug toxicity, and alteration of drug dosage is not required, although the total plasma concentration may be found to be considerably lower than normal. In addition to plasma protein binding, alteration of tissue binding must also be considered for the determination of the appropriate dosage of some drugs in renal disease.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Adler D.S. (1979): Phenytoin. Clin. Toxicol.,14, 147–150.
Antilla M., Haataja M. and Kasanen A. (1980): Pharmacokinetics of Naproxen in subjects with normal and impaired renal function. Europ. J. Clin. Pharmacol.,18, 263–268.
Aronson J.K. (1983): Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction. Clin. Pharmacokin.,8, 155–178.
Bachmann K., Shapiro R. (1977): Protein binding of coumarin anticoagulants in disease states. Clin. Pharmacokinet.,2, 110–126.
Bachmann K., Sullivan T.J. (1982): Effect of plasma protein binding on clearance of drugs metabolized by Michaelis-Menten kinetics. J. Pharm. Sei.,71, 374–375.
Belpaire F.M., Bogaert M.G. and Mussche M.M. (1977): Influence of acute renal failure on the protein binding of drugs in animal and in man. Europ. J. Clin. Pharmacol.,11, 27–32.
Bennett W.M., Muther R.S., Parker R.A., Feig P., Morrison G., Golper T.A. and Singer I. (1980): Drug therapy in renal failure : dosing guidelines for adults. Ann. Int. Med.,93, 286–325.
Bergrem H. (1983): Pharmacokinetics and protein binding of prednisolone in patients with nephrotic syndrome and patients undergoing hemodialysis. Kidney Int.,23, 876–888.
Blouin R.A., Erwin W.G., Dutro M.P., Bustrack J.A. and Rowse K.L. (1980): Chloramphenicol hemodialysis clearance. Therap. Drug Monitor,2, 351–354.
Bowmer C.J. and Lindup W.E. (1982): Decreased drug binding in uremia: effect of indoxyl sulfate and other endogenous substances on the binding of drugs and dyes ot human albumine. Biochem. Pharmacol.,31, 319–323.
Clegg L.S. and Lindup W.E. (1982): Drug binding defect of uremic plasma : unlikely involvement of carbamoylated albumin. Biochem. Pharmacol.,31, 2791–2794.
D’Arcy P.F. and McElnay J.C. (1982): Drug interactions involving the displacement of drugs from plasma protein and tissue binding sites. Pharmbc. Therap.,17, 211–220.
Frey F.J., Gambertoglio J.G., Frey B.M., Benet L.Z. and Amend W.J.C. (1982): Nonlinear plasma protein binding and haemodialysis clearance of prednisolone. Europ. J. Clin. Pharmacol.,23, 65–74.
Frey F.J. and Frey B.M. (1982): Altered prednisolone kinetics in patients with the nephrotic syndrome. Nephron.,32, 45–48.
Garcia M.J., Dominguez-Gil A., Tabernero J.M. and Sanchez Tomero J. A. (1979): Pharmacokinetics of cefoxitin in patients with normal or impaired renal function. Europ. J. clin. Pharmacol.,16, 119–124.
Giacomini K.M., Gibson T.P. and Levy G. (1978): Plasma protein binding of d-Propoxyphene in normal subjects and anephric patients. J. Clin. Pharm.,18, 106–109.
Giacomini K.M., Swezey S.E., Turner-Tamiyasu K. and Blaschke T.F. (1982): The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide. J. Pharmacokinet Biopharm.,10, 1–14.
Greenblatt D.J., Sellers E.M. and Koch-Weser J. (1982): Importance of protein binding for the interpretation of serum or plasma drug concentrations. J. Clin. Pharmacol.,22, 259–263.
Greenblatt D.J., Murray T.G., Audet P.R., Locniskar A., Koepke H.H. and Walker B.R. (1983): Multiple-dose kinetics and dialyzability of Oxazepam in renal insufficiency. Nephron.,34, 234–238.
Greene D.S. and Tice A.D. (1977): Effect of hemodialysis on Cefazolin protein binding. J. Pharm. Sei.,66, 1508–1510.
Gugler R., Shoeman D.W., Huffmann D.H., Cohlmia J.B. and Azarnoff D.L. (1975): Pharmacokinetics of drugs in patients with the nephrotic syndrome. J. Clin. Invest.,55, 1182–1189.
Holford N.H.G. and Sheiner L.B. (1981): Understanding the dose-effect relationship: clinical application of Pharmacokinetic-pharmacodynamic models. Clin. Pharmacokin.,6, 429–453.
Holley F.O., Fonganis K.V. and Stanski D.R. (1982): Effect of cardiopulmonary bypass on the pharmacokinetics of drugs. Clin. Pharmacokinet.,7, 234–251.
Houin G., Brunner F., Nebout T., Cherfoui M., Lagrue G. and Tillement J.P. (1983): The effect of chronic renal insufficiency on the pharmacokinetics of doxycycline in man. Br. J. Clin. Pharm.,16, 245–252.
Hulter H.N., Licht J.H., Illnick L.P. and Singh S. (1979): Clinical efficacy and pharmacokinetics of Clonidine in hemodialysis and renal insufficiency. J. Lab. Clin. Med.,94, 223–231.
Iliopoulou A., Downey K., Chaput de Saintonge D.M. and Turner P. (1982): Should erythromycin dose be altered in haemodialysis patients? Europ. J. Clin. Pharmacol.,23, 435–440.
Keller F., Hauff A., Schultze G., Offermann G., Reeck S., Molzahn M., Kreutz G. and Vöhringer H. F. (1984): Effect of repeated plasma exchange on steady state kinetics of digoxin and digitoxin. Arzneim. Forsch.,34, 83–86.
Kessler K.M. and Perez G.O. (1981): Decreased quinidine plasma protein binding during hemodialysis. Clin. Pharmacol. Therap.,30, 121–126.
Kinniburgh D.W. and Boyd N.D. (1981): Phenytoin binding to partially purified albumin in renal disease. Clin. Pharmacol. Therap.,29, 203–210.
Kragh-Hansen U. (1981): Molecular aspects of ligand binding to serum albumin. Pharmacol. Reviews,33, 17–53.
Kramer P., Koethe E., Saul J. and Scheler F. (1974): Uremic and normal plasma protein binding of various cardiac glycosides under ‘in vivo’ conditions. Europ. J. Clin. Invest.,4, 53–58.
Levy G. and Yacobi A. (1974): Effect of plasma protein binding on elimination of Warfarin. J. Pharm. Sei.,63, 805–806.
Levy G. (1976): Effect of plasma protein binding of drugs on duration and intensity of pharmacological activity. J. Pharm. Sei.,65, 1264–1265.
Levy R.H. and Moreland T.A. (1984): Rationale for monitoring free drug levels. Clin. Pharmacokin.,9 (SI), 1–9.
Lichtenwalder D.M., Suh B., Lorber B. and Rudnick M.R. (1982): Correction of drug binding defects in uremia in vitro by anion exchange resin treatment. Biochem. Pharmacol.,31, 3483–3487.
Lichtenwalder D.M., Suh B. and Lichtenwalner M.R. (1983):Isolation and chemical characterization of 2-hydroxybenzolglycine as a drug binding inhibitor in uremia. J. Clin. Invest.,71, 1289–1296.
Lima J.J. (1983): Experimental evidence for concentration-dependent plasma protein binding effects on the apparent half-lives of restrictively cleared drugs. J. Pharm. Sei.,72, 461–462.
Martin E., Gambertoglio J.G., Adler D.S., Tozer T.N., Roman L.A. and Gransz H. (1977): Removal of phenytoin by hemodialysis in uremic patients. J. Am. Med. Assoc.,238, 1750–1753.
McNamara P.J., Gibaldi M. and Stoeckel K. (1983): Volume of distribution terms for a drug (Ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations. Europ. J. Clin. Pharmacol.,25, 399–405.
Naranjo CA., Khouw V. and Sellers E.M. (1982): Nonfatty acid-modulated variations in drug binding due to Heparin. Clin. Pharmacol. Therap.,31, 746–752.
Odar-Cederlöf J., Borga O. (1974): Kinetics of Diphenyl-hydantoin inuraemic patients: consequences of decreased plasma protein binding. Europ. J. Clin. Pharmacol.,7, 31–37.
Odar-Cederlöf I. (1977): Plasma protein binding of Phenytoin and Warfarin in patients undrgoing renal transplantation. Clin. Pharmacokinet.,2, 147–153.
O’Malley K., Velasco M., Pruitt S. and McNay J.L. (1975): Decreased plasma protein binding of diazoxide in uremia. Clin. Pharmacol. Therap.,18, 53–58.
Pearson R.M. and Breckenridge A.M. (1976): Renal function, protein binding and pharmacological response to diazoxide. Br. J. Clin. Pharm.,3, 169–175.
Piafsky K.M. (1980): Disease-induced changes in the plasma binding of basic drugs. Clin. Pharmacokinet.,5, 246–262.
Rane A., Villeneuve J. P., Stone W.J., Nies A.S., Wilkinson G.R. and Branch R.A. (1978): Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin. Pharmacol. Therap.,24, 199–207.
Reidenberg M.M., Odar-Cederlöf J., Von Bah C, Borga O. and Sjöqvist F. (1971): Protein binding of Diphenylhydantoin and Desmethylimipramine in plasma form patients with poor renal function. N. Engl. J. Med.,285, 264–267.
Reidenberg M.M. and Drayer D.E. (1984): Alteration of drug-protein binding in renal disease. Clin. Pharmacokin.,9, (SI), 18–26.
Richens A. (1979): Clinical pharmacokinetics of phenytoin. Clin. Pharmacokin.,4, 153–169.
Rimmer E.M., Buss D.C., Routledge P.A. and Richens A. (1984): Should we routinely measure free plasma phenytoin concentration? Br. J. Clin. Pharm.,17, 99–102.
Robertz G.M. and Dengler H.J. (1983): Endogenous ligand(s) decrease drug-protein binding in uremic sera: a fluorescence probe study. Klin. Wochenschr.,61, 649–653.
Rowland M. (1972): Influence of route of administration on drug availability. J. Pharm. Sei.,61, 70–74.
Schneider R.E., Bishop H. (1982): β-blocker plasma concentration and inflammatory disease : clinical implications. Clin. Pharmacokinet.,7, 281–284.
Singhvi S.M., Heald A.F. and Schreiber E.C. (1978): Pharmacokinetics of cephalosporin antibiotics: protein-binding considerations. Chemotherapy,24, 121–133.
Steele W.H., Lawrence J.R., Elliott H.L. and Whiting B. (1979): Alteration of phenytoin protein binding with in vivo haemodialysis in dialysis encephalopathy. Europ. J. Clin. Pharmacol.,15, 69–71.
Storstein L. (1977): Protein binding of cardiac glycosides in disease states. Clin. Pharmacokinet.,2, 220–233.
Tozer T.N. (1981): Concepts basic to pharmacokinetics. Pharmacol. Therap.,12, 109–131.
Verbeeck R.K. and De Schepper P.J. (1980): Influence of chronic renal failure and hemodialysis on diflunisal plasma protein binding. Clin. Pharmacol. Therap.,27, 628–635.
Wilkinson G.R. and Shand D.G. (1975): A physiological approach to hepatic drug clearance. Clin. Pharmacol. Therap.,18, 377–390.
Yeung J.H.K., Breckenridge A.M. and Park B.K. (1983): Drug-protein conjugates — IV. The effect of acute renal failure on the disposition of (14C)Captopril in the rat. Biochem. Pharmacol.,32, 2467–2472.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Keller, F., Maiga, M., Neumayer, H.H. et al. Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. European Journal of Drug Metabolism and Pharmacokinetics 9, 275–282 (1984). https://doi.org/10.1007/BF03189651
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03189651